Skip to main content
    D

    Dermata Therapeutics Inc (DRMA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.60
    -0.02 (-3.65%)

    Market Cap: $3.06M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    Dermata Therapeutics Inc (DRMA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Dermata Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$7.56M, operating cash flow was -$7.76M and free cash flow was -$7.76M. The quarter ended Sep 30, 2026 had revenue of $74.14K and net income of -$2.82M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $7.77M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Cost of revenue$0$0$0$0$0$0$1.35K
    Gross profit$0$0$0$0$0$0-$1.35K
    Research and development$2.93M$8.20M$4.07M$5.65M$3.46M$1.61M$2.62M
    Operating income-$7.77M-$12.51M-$8.04M-$9.67M-$7.86M-$3.17M-$4.47M
    Net income-$7.56M-$12.29M-$7.79M-$9.61M-$7.90M-$3.24M-$4.72M
    EBITDA-$7.77M-$12.51M-$8.04M-$9.67M-$7.84MN/A-$4.47M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$74.14K$0$0$0$0$0$0$0$0$0$0$0
    Gross profit$40.13K$0$0N/A$0$0$0N/A$0$0$0N/A
    Operating income-$2.86M-$3.01M-$1.93M-$1.90M-$1.76M-$1.77M-$2.34M-$3.20M-$3.23M-$2.88M-$3.20M-$2.22M
    Net income-$2.82M-$2.97M-$1.85M-$1.86M-$1.69M-$1.70M-$2.30M-$3.15M-$3.17M-$2.83M-$3.13M-$2.13M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $7.52M were 95.7% of total assets of $7.86M, against total liabilities of $1.64M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$7.86M$3.53M$7.98M$6.94M$11.62M$605.45K$2.07M
    Current assets$7.86M$3.53M$540.50K$703.19K$11.62M$605.45K$2.07M
    Cash and equivalents$7.52M$3.16M$7.44M$6.24M$10.80M$530.40K$1.99M
    Total liabilities$1.64M$1.97M$1.62M$922.63K$1.52M$3.78M$2.28M
    Short-term debtN/AN/AN/AN/AN/A$556.16K$730.55K
    Long-term debtN/AN/AN/AN/AN/AN/A$553.19K
    Shareholder equity$6.22M$1.56M$6.36M$6.02M$10.11M-$3.18M-$210.16K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$6.64M$5.32M$7.47M$7.86M$5.07M$6.64M$10.01M$3.53M$6.69M$5.24M$5.18M$7.98M
    Total liabilities$2.73M$1.83M$1.05M$1.64M$1.11M$1.03M$2.70M$1.97M$1.95M$1.92M$1.37M$1.62M
    Cash and equivalents$4.82M$4.41M$6.95M$7.52M$4.66M$6.48M$9.72M$3.16M$6.14M$4.95M$4.73M$7.44M
    Shareholder equity$3.91M$3.49M$6.41M$6.22M$3.96M$5.61M$7.30M$1.56M$4.74M$3.32M$3.81M$6.36M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$7.76M-$11.16M-$6.41M-$8.83M-$5.69M-$4.03M-$3.92M
    Capital expenditures$0$0$0$4$0$0$0
    Free cash flow-$7.76M-$11.16M-$6.41M-$8.83M-$5.69M-$4.03M-$3.92M
    Dividends paidN/AN/AN/AN/A$2.29MN/AN/A
    Share repurchases$50.49K$0N/AN/AN/AN/AN/A
    Financing cash flow$12.12M$6.89M$7.61M$4.28M$15.96M$2.57M$4.73M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.65M-$2.42M-$2.48M-$1.33M-$1.80M-$2.69M-$1.93M-$2.91M-$3.42M-$2.13M-$2.70M-$1.15M
    Capital expenditures$52.98KN/A$0$3$5$0$4$4$3$3$0$5
    Free cash flow-$2.70MN/A-$2.48M-$1.33M-$1.80M-$2.69M-$1.93M-$2.91M-$3.42M-$2.13M-$2.70M-$1.15M
    Last 12 quarters

    Frequently Asked Questions About DRMA

    What is Dermata Therapeutics' annual revenue?

    Dermata Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Dermata Therapeutics profitable?

    No. Dermata Therapeutics reported net income of -$7.56M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does DRMA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$7.76M minus capital expenditures of $0 produced free cash flow of -$7.76M.

    How much debt does Dermata Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $7.52M.